NO20045005L - Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid - Google Patents

Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid

Info

Publication number: NO20045005L
Authority: NO; Norway
Prior art keywords: blocker; calcium channel; administering; cardiac glycoside; adenosine agonist
Prior art date: 2002-04-18

Application number

NO20045005A

Other languages

English (en)

Norwegian (no)

Inventor

Luiz Belardinelli

Arvinder Dhalla

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-18

Filing date

2004-11-17

Publication date

2004-11-17

2004-11-17 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2004-11-17 Publication of NO20045005L publication Critical patent/NO20045005L/no

Links

229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
206010003119 arrhythmia Diseases 0.000 title abstract 2
230000006793 arrhythmia Effects 0.000 title abstract 2
239000002876 beta blocker Substances 0.000 title abstract 2
229940097320 beta blocking agent Drugs 0.000 title abstract 2
239000000480 calcium channel blocker Substances 0.000 title abstract 2
229940097217 cardiac glycoside Drugs 0.000 title abstract 2
239000002368 cardiac glycoside Substances 0.000 title abstract 2
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 title abstract 2
239000003379 purinergic P1 receptor agonist Substances 0.000 title abstract 2
229930002534 steroid glycoside Natural products 0.000 title abstract 2
101150007969 ADORA1 gene Proteins 0.000 abstract 1
229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

NO20045005A 2002-04-18 2004-11-17 Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid NO20045005L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37376602P	2002-04-18	2002-04-18
PCT/US2003/012043 WO2003088978A1 (en)	2002-04-18	2003-04-18	Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (1)

Publication Number	Publication Date
NO20045005L true NO20045005L (no)	2004-11-17

Family

ID=29251078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045005A NO20045005L (no)	2002-04-18	2004-11-17	Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid

Country Status (17)

Country	Link
US (3)	US7005425B2 (de)
EP (1)	EP1494685B1 (de)
JP (1)	JP2005530736A (de)
KR (1)	KR20040106354A (de)
CN (2)	CN101385738A (de)
AT (1)	ATE418991T1 (de)
AU (1)	AU2003235466C1 (de)
CA (1)	CA2482928A1 (de)
DE (1)	DE60325572D1 (de)
ES (1)	ES2318129T3 (de)
IL (1)	IL164652A0 (de)
MX (1)	MXPA04010285A (de)
NO (1)	NO20045005L (de)
NZ (1)	NZ536001A (de)
RU (1)	RU2332220C2 (de)
WO (1)	WO2003088978A1 (de)
ZA (1)	ZA200408411B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL351484A1 (en)	1999-03-23	2003-04-22	Univ James Cook	Organ arrest, protection and preservation
USRE47351E1 (en)	1999-06-22	2019-04-16	Gilead Sciences, Inc.	2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
AU2001238665A1 (en)	2000-02-23	2001-09-03	Cv Therapeutics, Inc.	Method of identifying partial agonists of the a2a receptor
US7157440B2 (en) *	2001-07-13	2007-01-02	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) *	2002-07-11	2010-05-11	Cv Therapeutics, Inc.	Partial and full agonists A1 adenosine receptors
ATE418991T1 (de) *	2002-04-18	2009-01-15	Cv Therapeutics Inc	Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US8470801B2 (en)	2002-07-29	2013-06-25	Gilead Sciences, Inc.	Myocardial perfusion imaging methods and compositions
GB2436255B (en) *	2002-12-23	2007-11-28	Global Cardiac Solutions Pty L	Organ preconditioning, arrest, protection, preservation and recovery
CN1980946A (zh) *	2004-07-12	2007-06-13	Cv医药有限公司	用于制备a1腺苷受体激动剂的方法
US20060019954A1 (en) *	2004-07-20	2006-01-26	Cedars-Sinai Medical Center	Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) *	2004-08-30	2007-11-27	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
RU2389798C2 (ru)	2004-09-14	2010-05-20	Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт	Способ лечения буциндололом, основанный на определении генотипа
US7822474B2 (en) *	2005-11-30	2010-10-26	Cedars-Sinai Medical Center	Methods for the prediction of arrhythmias and prevention of sudden cardiac death
KR20080090491A (ko)	2006-02-03	2008-10-08	씨브이 쎄러퓨틱스, 인코포레이티드	Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
AU2006345361B2 (en)	2006-05-29	2014-04-10	Hibernation Therapeutics, A Kf Llc	Improved tissue maintenance
JP2009544628A (ja)	2006-07-25	2009-12-17	ハイバーネイションセラピューティクスリミテッド	外傷治療
EP2173353B1 (de)	2007-03-02	2015-05-06	Hibernation Therapeutics, a KF LLC	Zusammensetzung mit Adenosin und Lignocain
JP5623288B2 (ja)	2007-12-21	2014-11-12	エイオーピーオーファンファーマスーティカルズアクチエンゲゼルシャフトＡＯＰＯｒｐｈａｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	医薬組成物
RU2011115815A (ru) *	2008-09-29	2012-11-10	Гайлид Сайэнсиз, Инк. (Us)	Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
GB0903299D0 (en)	2009-02-26	2009-04-08	Guys And St Thomas Nhs Foundat	Composition and methods
US8974828B2 (en) *	2009-03-18	2015-03-10	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2011019752A2 (en)	2009-08-14	2011-02-17	Gilead Palo Alto, Inc.	A1 adenosine receptor agonist polymorphs
LT2523669T (lt)	2010-01-11	2017-04-25	Inotek Pharmaceuticals Corporation	Akispūdžio mažinimo būdas, derinys ir rinkinys
LT2555776T (lt) *	2010-03-19	2017-04-25	Inotek Pharmaceuticals Corporation	Adenozino a1 agonistų ir neselektyvių beta adrenerginių receptorių blokatorių derinio kompozicijos, skirtos akispūdžio mažinimui
CA2792266A1 (en)	2010-03-26	2011-09-29	Inotek Pharmaceuticals Corporation	Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20120005128A1 (en) *	2010-06-29	2012-01-05	Sanofi	Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
PL2807178T3 (pl)	2012-01-26	2017-12-29	Inotek Pharmaceuticals Corporation	Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
WO2014152723A1 (en)	2013-03-15	2014-09-25	Inotek Pharmaceuticals Corporation	Ophthalmic formulations
BR112016000809A2 (pt)	2013-07-17	2017-08-22	Hibernation Therapeuitics A Kf Llc	Método para tratar infecção, sepsia e lesão
US20160310524A1 (en) *	2013-12-13	2016-10-27	Ralph Ankenman	Compositions and methods for treating dysregulated systems
CN114847965A (zh)	2016-02-01	2022-08-05	英凯达治疗公司	电子监测联合吸入药理学疗法管理心律失常
CN106370754B (zh) *	2016-11-07	2019-03-08	西安科技大学	基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
US10441537B2 (en)	2017-05-10	2019-10-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
US10799138B2 (en)	2018-04-05	2020-10-13	University Of Maryland, Baltimore	Method of administering sotalol IV/switch
US11610660B1 (en)	2021-08-20	2023-03-21	AltaThera Pharmaceuticals LLC	Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en)	2021-08-20	2025-08-26	AltaThera Pharmaceuticals LLC	Anti-arrhythmic compositions and methods
US11344518B2 (en)	2018-08-14	2022-05-31	AltaThera Pharmaceuticals LLC	Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en)	2018-08-14	2019-12-24	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en)	2018-08-14	2023-07-11	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
JP7156154B2 (ja) *	2019-04-18	2022-10-19	株式会社島津製作所	培地処理システム及び培地処理方法
KR102891439B1 (ko)	2019-08-01	2025-11-25	인카다 테라퓨틱스, 인크.	항부정맥 제제
US11007185B2 (en)	2019-08-01	2021-05-18	Incarda Therapeutics, Inc.	Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5108363A (en) *	1988-02-19	1992-04-28	Gensia Pharmaceuticals, Inc.	Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) *	1993-10-28	1998-04-07	University Of Florida Research Foundation, Inc.	N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
AU722110B2 (en) *	1996-06-28	2000-07-20	Merck & Co., Inc.	Pharmaceutical preparation
US5789416B1 (en) *	1996-08-27	1999-10-05	Cv Therapeutics Inc	N6 mono heterocyclic substituted adenosine derivatives
EP0966274B1 (de) *	1997-01-31	2002-06-12	The Board Of Trustees Of The Leland Stanford Junior University	Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
CO5180581A1 (es) *	1999-09-30	2002-07-30	Pfizer Prod Inc	Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6576620B2 (en) *	1999-12-03	2003-06-10	Cv Therapeutics, Inc.	Method of identifying partial adenosine A1 receptor agonists
US6605597B1 (en) *	1999-12-03	2003-08-12	Cv Therapeutics, Inc.	Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
JP2004508336A (ja) *	2000-09-08	2004-03-18	スィーヴィー　セラピューティクス　インコーポレイテッド	抗不整脈薬としてのプリンリボシド
US6946449B2 (en) *	2001-07-13	2005-09-20	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
ATE418991T1 (de) *	2002-04-18	2009-01-15	Cv Therapeutics Inc	Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

2003
- 2003-04-18 AT AT03724098T patent/ATE418991T1/de not_active IP Right Cessation
- 2003-04-18 EP EP03724098A patent/EP1494685B1/de not_active Expired - Lifetime
- 2003-04-18 CN CNA2008101711378A patent/CN101385738A/zh active Pending
- 2003-04-18 MX MXPA04010285A patent/MXPA04010285A/es active IP Right Grant
- 2003-04-18 RU RU2004130826/14A patent/RU2332220C2/ru not_active IP Right Cessation
- 2003-04-18 US US10/418,654 patent/US7005425B2/en not_active Expired - Fee Related
- 2003-04-18 DE DE60325572T patent/DE60325572D1/de not_active Expired - Lifetime
- 2003-04-18 AU AU2003235466A patent/AU2003235466C1/en not_active Ceased
- 2003-04-18 KR KR10-2004-7016764A patent/KR20040106354A/ko not_active Abandoned
- 2003-04-18 CA CA002482928A patent/CA2482928A1/en not_active Abandoned
- 2003-04-18 NZ NZ536001A patent/NZ536001A/en not_active IP Right Cessation
- 2003-04-18 JP JP2003585730A patent/JP2005530736A/ja active Pending
- 2003-04-18 CN CNA038086999A patent/CN1646142A/zh active Pending
- 2003-04-18 ES ES03724098T patent/ES2318129T3/es not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012043 patent/WO2003088978A1/en not_active Ceased
2004
- 2004-10-18 IL IL16465204A patent/IL164652A0/xx unknown
- 2004-10-18 ZA ZA200408411A patent/ZA200408411B/en unknown
- 2004-11-17 NO NO20045005A patent/NO20045005L/no not_active Application Discontinuation
2005
- 2005-10-28 US US11/262,025 patent/US7479485B2/en not_active Expired - Fee Related
2009
- 2009-01-09 US US12/351,731 patent/US20090118221A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7005425B2 (en)	2006-02-28
KR20040106354A (ko)	2004-12-17
NZ536001A (en)	2006-05-26
ZA200408411B (en)	2006-02-22
US7479485B2 (en)	2009-01-20
US20090118221A1 (en)	2009-05-07
US20030216349A1 (en)	2003-11-20
CN1646142A (zh)	2005-07-27
ATE418991T1 (de)	2009-01-15
RU2004130826A (ru)	2005-05-10
MXPA04010285A (es)	2005-02-03
US20060052333A1 (en)	2006-03-09
AU2003235466A1 (en)	2003-11-03
EP1494685B1 (de)	2008-12-31
EP1494685A1 (de)	2005-01-12
RU2332220C2 (ru)	2008-08-27
WO2003088978A1 (en)	2003-10-30
ES2318129T3 (es)	2009-05-01
AU2003235466C1 (en)	2008-03-20
DE60325572D1 (de)	2009-02-12
IL164652A0 (en)	2005-12-18
CA2482928A1 (en)	2003-10-30
JP2005530736A (ja)	2005-10-13
CN101385738A (zh)	2009-03-18

Legal Events

Date	Code	Title	Description
2011-11-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20045005L (no)	2004-11-17	Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid
TW200500355A (en)	2005-01-01	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2003097052A3 (en)	2003-12-18	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
AR029198A1 (es)	2003-06-18	Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos
BR0306919A (pt)	2004-11-09	Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
YU10699A (sh)	2001-07-10	Upotreba glp-1, glp-1 analoga i glp-1 derivata za proizvodnju leka
NO20060871L (no)	2006-04-24	Azepinderivater som farmasoytiske midler
BR9909277A (pt)	2001-10-16	Compostos com atividade em receptores muscarìnicos
AR119158A1 (es)	2021-12-01	Tratamientos de angioedema hereditario
IL157841A0 (en)	2004-03-28	Activation of natural killer cells by adenosine a3 receptor agonists
BR0316157A (pt)	2005-09-27	Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina
NO20024646L (no)	2002-10-15	Kombinasjonsterapier med vaskul¶r-skadende aktivitet
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
EP1348466A3 (de)	2003-10-29	Schmerzbehandlung mit Adenosin-Tetraphosphaten
CO5190664A1 (es)	2002-08-29	Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
BR0215288A (pt)	2004-12-21	Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente
ES2136581A1 (es)	1999-11-16	Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
BR9814867A (pt)	2000-10-03	Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
WO2022099060A3 (en)	2022-06-16	Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
IL154652A0 (en)	2003-09-17	Purine ribosides as antiarrhythmics
Hönigsmann et al.	2009	Photo (chemo) therapy for cutaneous T-cell lymphoma
AR006382A1 (es)	1999-08-25	Procedimiento para el tratamiento del envejecimiento cutaneo y de lesiones atroficas mediante la administracion de una preparacion conteniendoacido hialuronico y/o hialuronatos.
ECSP003771A (es)	2001-07-27	Metodo para prevenir la diarrea